<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658697</url>
  </required_header>
  <id_info>
    <org_study_id>08-004</org_study_id>
    <nct_id>NCT00658697</nct_id>
  </id_info>
  <brief_title>Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer</brief_title>
  <official_title>A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising Prostate Specific Antigen (PSA) After Local Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early
      multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen
      deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising
      Prostate Specific Antigen (PSA) after treatment of their prostate cancer with surgery or
      radiation)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A single arm phase 2 study designed to evaluate the rate of patients free from Prostate
      Specific Antigen (PSA) progression (TTP) one year after completing ADT for men with BCR after
      definitive local therapy for prostate cancer.

      The null and alternative TTP rate were 41% and 60% respectively. A sample size of 42 would
      provide 80% power to detect the difference with a 2-sided type I error rate of 0.05.'

      The primary objective was to evaluate the proportion of patients free from PSA progression
      after completing one year of ADT

      The secondary objectives included

        1. PSA response (&lt; 0.2 ng/mL and &lt; 0.01) at completion of docetaxel/bevacizumab, at
           completion of ADT and one year off ADT

        2. Correlation of PSA response and TTP

        3. Toxicity

        4. Testosterone recovery at 6, 12 months off ADT

      Treatment schedule details are as follows:

        -  Each treatment cycle lasts three weeks. During the first three months, participants will
           receive the Avastin and docetaxel on day 1 of each three-week cycle for a total of four
           doses of docetaxel/Avastin. Avastin and docetaxel are administered intravenously. The
           Avastin will continue to be given every three weeks after the docetaxel is completed for
           a total of 17 doses (one year) of Avastin therapy.

        -  Participants will receive zoladex (or lupron) on day 1 of the first cycle and then every
           3 months for a total of 18 months. Zoladex is administered subcutaneously and Lupron is
           administered intramuscularly.

        -  Bicalutamide pills will be started at the completion of docetaxel chemotherapy (start of
           month 4) and will be taken once daily until hormone therapy is completed (total of 15
           months).

        -  During all treatment cycles, the participant will have a physical exam and will be asked
           questions about their general health and specific questions about any problems they
           might be experiencing. Blood work will be performed every three weeks for the first
           three months and then every three months while on hormone therapy and during follow-up.

        -  After the final treatment participants will have a follow-up visit every three months
           for the first two years, every 4 months for the third year and every 6 months for years
           4 and 5.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT)</measure>
    <time_frame>participants were followed for the duration of the study, an average of 2 years</time_frame>
    <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL.
For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt;2.0 ng/mL.
Any new site of metastatic disease on imagining would be considered progression regardless of PSA value Clinical assessments (Vitals, Physical Exam, Performance Status, PSA and testosterone) were performed every 3 months starting at completion of hormone therapy until PSA progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With PSA Responses at One Year After the Completion of ADT</measure>
    <time_frame>1 year + 3 month off last ADT injection</time_frame>
    <description>The PSA response was defined using two cut-offs: PSA &lt;0.2 ng/mL or PSA &lt;0.01 ng/mL at the one year after completion of ADT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PSA Progression (TTP)</measure>
    <time_frame>participants were followed for the duration of the study, an average of 2 years</time_frame>
    <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL. For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt; 2.0 ng/mL. Any new site of metastatic disease on imagining would be considered progression regardless of PSA value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Testosterone Recovery</measure>
    <time_frame>2 years</time_frame>
    <description>Testosterone recovery was defined as &gt;100 or within DFCI institute normal range (240-950) at one year after the completion of ADT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Assessed each cycle throughout treatment form time of first dose to 30 days post-treatment, up to 2 years</time_frame>
    <description>Treatment related adverse events were graded based on CTCAE v. 3.0.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel, Bevacizumab, and ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
    <description>Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles</description>
    <arm_group_label>Docetaxel, Bevacizumab, and ADT</arm_group_label>
    <other_name>Taxotere, Docecad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles</description>
    <arm_group_label>Docetaxel, Bevacizumab, and ADT</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADT</intervention_name>
    <description>Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)</description>
    <arm_group_label>Docetaxel, Bevacizumab, and ADT</arm_group_label>
    <other_name>Lupron or Zoladex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Starting on day 84 orally once daily until hormone therapy is completed</description>
    <arm_group_label>Docetaxel, Bevacizumab, and ADT</arm_group_label>
    <other_name>Casodex, Cosudex, Calutide, Kalumid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  History of biopsy documented prostate cancer (any Gleason score)

          -  Past treatment with prostatectomy with our without salvage prostate/pelvic radiation
             or primary radiation

          -  If past prostatectomy, pathologic stage no greater than T1-3, N1, M0

          -  PSA recurrence with PSAdt 8 months or less. There is no minimum PSA for prostatectomy
             patients. For patients treated with primary radiation therapy PSA should be 2.0ng/ml
             or greater

          -  No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis on CXR

          -  Prior ADT allowed if less than 6 months and testosterone recovered to within 50 units
             of normal range

          -  ECOG Performance status of 0-1

          -  Absolute neutrophil count of 1,500 mm3 or greater

          -  Platelet Count 100,000 mm3 or greater

          -  Total bilirubin within normal limits

          -  HG 8gm/dl or greater

          -  Testosterone within 50 units of normal range

          -  No history of bleeding or thromboses within the last 12 months that required medical
             intervention

        Exclusion Criteria:

          -  History of cancer within 5 years, other than prostate cancer and non-melanoma skin
             cancer

          -  Medical condition requiring concomitant corticosteroids

          -  Active infection

          -  Prior chemotherapy

          -  Neuropathy requiring medical therapy

          -  Documented local recurrence or metastatic prostate cancer

          -  Inability to comply with study and/or follow-up procedures

          -  Life expectancy of less than 2 years

          -  Current, recent (within 4 weeks of first infusion of this study), or planned
             participation in an experimental drug study other than a Genentech-sponsored Avastin
             cancer study

          -  Inadequately controlled hypertension

          -  Any prior history of hypertensive crisis or hypertensive encephalopathy

          -  NYHA Grade II or greater congestive heart failure

          -  History of myocardial infarction or unstable angina within 12 months prior to study
             enrollment

          -  History of stroke or transient ischemic attack at any time

          -  Known CNS disease

          -  Significant vascular disease

          -  Symptomatic peripheral vascular disease

          -  Evidence of bleeding diathesis or coagulopathy

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to study enrollment or anticipation of need for major surgical procedure during
             the course of the study

          -  Core biopsy or other minor surgical procedure, excluding placement of a vascular
             access device, within 7 days prior to enrollment

          -  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
             within 6 months prior to study enrollment

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Proteinuria at screening

          -  Known hypersensitivity to any component of Avastin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary-Ellen Taplin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Maryland - Greenebaum Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 9, 2008</study_first_submitted>
  <study_first_submitted_qc>April 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <results_first_submitted>July 29, 2015</results_first_submitted>
  <results_first_submitted_qc>July 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2015</results_first_posted>
  <last_update_submitted>April 27, 2017</last_update_submitted>
  <last_update_submitted_qc>April 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Mary-Ellen Taplin, MD</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, HMS</investigator_title>
  </responsible_party>
  <keyword>Rising PSA</keyword>
  <keyword>androgen deprivation</keyword>
  <keyword>bevacizumab (avastin)</keyword>
  <keyword>docetaxel</keyword>
  <keyword>lupron</keyword>
  <keyword>zoladex</keyword>
  <keyword>bicalutamide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>42 patients were enrolled between June 2, 2008 to December 14, 2010 at Dana Farber Cancer Institute and University of Michigan. One patient never started any study treatment, and was excluded from analysis.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel, Bevacizumab, and ADT</title>
          <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel
Bevacizumab: intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>41 (One patient never started any study treatment, and was excluded from analysis).</population>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel, Bevacizumab, and Androgen Deprivation Therapy (ADT)</title>
          <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
Androgen deprivation therapy (ADT) or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel
Bevacizumab: intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="55" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With PSA Responses at One Year After the Completion of ADT</title>
        <description>The PSA response was defined using two cut-offs: PSA &lt;0.2 ng/mL or PSA &lt;0.01 ng/mL at the one year after completion of ADT.</description>
        <time_frame>1 year + 3 month off last ADT injection</time_frame>
        <population>The analysis comprised of all patients received at least one treatment and had PSA data available* for the assessment of PSA responses at one year after completing ADT
*Note excluded 5 patients started treatments but had no PSA information at one year.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel, Bevacizumab, and ADT</title>
            <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With PSA Responses at One Year After the Completion of ADT</title>
          <description>The PSA response was defined using two cut-offs: PSA &lt;0.2 ng/mL or PSA &lt;0.01 ng/mL at the one year after completion of ADT.</description>
          <population>The analysis comprised of all patients received at least one treatment and had PSA data available* for the assessment of PSA responses at one year after completing ADT
*Note excluded 5 patients started treatments but had no PSA information at one year.</population>
          <units>percentage of participants with data</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PSA &lt;0.2 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="28" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PSA &lt;=0.01 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25" lower_limit="12" upper_limit="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PSA Progression (TTP)</title>
        <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL. For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt; 2.0 ng/mL. Any new site of metastatic disease on imagining would be considered progression regardless of PSA value</description>
        <time_frame>participants were followed for the duration of the study, an average of 2 years</time_frame>
        <population>the analysis dataset is comprised of all treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel, Bevacizumab, and ADT</title>
            <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PSA Progression (TTP)</title>
          <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL. For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt; 2.0 ng/mL. Any new site of metastatic disease on imagining would be considered progression regardless of PSA value</description>
          <population>the analysis dataset is comprised of all treated patients</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" lower_limit="26" upper_limit="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Testosterone Recovery</title>
        <description>Testosterone recovery was defined as &gt;100 or within DFCI institute normal range (240-950) at one year after the completion of ADT</description>
        <time_frame>2 years</time_frame>
        <population>All treated patients with assessable testosterone level data</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel, Bevacizumab, and ADT</title>
            <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
          </group>
        </group_list>
        <measure>
          <title>Testosterone Recovery</title>
          <description>Testosterone recovery was defined as &gt;100 or within DFCI institute normal range (240-950) at one year after the completion of ADT</description>
          <population>All treated patients with assessable testosterone level data</population>
          <units>percentage of participants with data</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Testosterone &gt;=100 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83" lower_limit="66" upper_limit="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Testosterone &gt;=240 ng/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35" lower_limit="31" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT)</title>
        <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL.
For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt;2.0 ng/mL.
Any new site of metastatic disease on imagining would be considered progression regardless of PSA value Clinical assessments (Vitals, Physical Exam, Performance Status, PSA and testosterone) were performed every 3 months starting at completion of hormone therapy until PSA progression.</description>
        <time_frame>participants were followed for the duration of the study, an average of 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel, Bevacizumab, and ADT</title>
            <description>Docetaxel: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH): Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel
Bevacizumab: intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
          </group>
        </group_list>
        <measure>
          <title>Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT)</title>
          <description>For prostatectomy patients: at least two serial rising PSA from treatment nadir and PSA &gt; 0.2 ng/mL.
For patient receiving radiation therapy alone as primary local therapy, at least two serial rising PSA from treatment nadir and PSA &gt;2.0 ng/mL.
Any new site of metastatic disease on imagining would be considered progression regardless of PSA value Clinical assessments (Vitals, Physical Exam, Performance Status, PSA and testosterone) were performed every 3 months starting at completion of hormone therapy until PSA progression.</description>
          <units>percentage of participants with data</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" lower_limit="93" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity</title>
        <description>Treatment related adverse events were graded based on CTCAE v. 3.0.</description>
        <time_frame>Assessed each cycle throughout treatment form time of first dose to 30 days post-treatment, up to 2 years</time_frame>
        <population>All patients received at least one study therapies</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel, Bevacizumab, and ADT</title>
            <description>Docetaxel: Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab: Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH): Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel
Bevacizumab: ntravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
          </group>
        </group_list>
        <measure>
          <title>Toxicity</title>
          <description>Treatment related adverse events were graded based on CTCAE v. 3.0.</description>
          <population>All patients received at least one study therapies</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 treatment related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 4 treatment related AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed each cycle throughout treatment form time of first dose and up to day 30 post-treatment, up to 2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel, Bevacizumab, and ADT</title>
          <description>Docetaxel:
Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
Bevacizumab:
Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT or Luteinizing hormone-releasing hormone agonist (LHRH):
Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide:
Oral Bicalutamide on day 84 once daily (after completing docetaxel, at 3 month) at dose of 50 mg for a total 15 months (4-18 months)
Docetaxel
Bevacizumab: ntravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
ADT: Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
Bicalutamide: Starting on day 84 orally once daily until hormone therapy is completed</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hematologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thrombotic microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Lower GI= hemorrhage NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomach= hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Perforation= appendix</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut= muscle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut= wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision-blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tearing</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhea w/o prior colostomy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis by exam= oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muco/stomatitis (symptom) oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>GI-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anus= hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oral cavity= hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rectum= hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdomen= pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Oral cavity= pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomach= pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fever w/o neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rigors/chills</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema limb</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Edema trunk/genital</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain-other</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flu-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection Gr0-2 neut= oral cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection Gr0-2 neut= skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC dental-tooth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection w/ unk ANC upper airway NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight gain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>ALT= SGPT</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>AST= SGOT</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Nonneuropathic generalized weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscular/skeletal hypoplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Back= pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Buttock= pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Extremity-limb= pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Joint= pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Muscle= pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Taste disturbance</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Mental status</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neuropathy CN V jaw / face-sensory</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neurologic-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Head/headache</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Libido</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Incontinence urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast= pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Scrotum= pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Testicle= pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Erectile impotence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gynecomastia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sexual/Reproductive function-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nose= hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Throat/pharynx/larynx= pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nasal cavity/paranasal sinus reaction</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pleural effusion (non-malignant)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Voice changes/dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pulmonary/Upper Respiratory-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Sweating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rash: acne/acneiform</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hand-foot reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Skin-other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hot flashes</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rana R. McKay, MD</name_or_title>
      <organization>DFCI</organization>
      <phone>6176323237</phone>
      <email>rana_yehia@dfci.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

